Medical condition
General
General is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- duloxetine (APO-DULOXETINE) Nervous system (N06)
- vigabatrin (SABRIL) Nervous system (N03)
- azathioprine (APO-AZATHIOPRINE) Antineoplastic and immunomodulating agents (L04)
- enoxaparin sodium (CLEXANE FORTE SAFETY-LOCK) Blood and blood forming organs (B01)
- eslicarbazepine acetate (ZEBINIX) Nervous system (N03)
- pregabalin (APO-PREGABALIN) Nervous system (N02)
- perampanel (FYCOMPA) Nervous system (N03)
- brivaracetam (BRIVIACT) Nervous system (N03)
- levetiracetam (APO-LEVETIRACETAM) Nervous system (N03)
- lacosamide (LACOMED) Nervous system (N03)
- stiripentol (DIACOMIT) Nervous system (N03)
- efgartigimod alfa (VYVGART) Antineoplastic and immunomodulating agents (L04)
Latest General news
Navigating Human Research: Mass General Brigham's IRB Guidance for Ethical Clinical Trials
This whitepaper summarizes Mass General Brigham's Institutional Review Board (IRB) Guidance, offering essential information for researchers and institutions involved in human subject research.
Surgeon General's Warning on Children's Screen Time: A Pharma Industry Analysis
The U.S. Surgeon General has issued a public health advisory highlighting the risks of excessive screen time for children and adolescents. This analysis explores the downstream effects on the pharmaceutical sector.
Tech Initiatives at Summa Health Post-General Catalyst Acquisition
This article discusses the technology initiatives at Summa Health following its acquisition by General Catalyst, highlighting key insights for B2B readers.
Mass General Brigham's Life-Saving Claims: A Closer Look
Mass General Brigham claims to be saving more lives, but some doctors express skepticism. This article explores the implications for the pharmaceutical industry.
Kennedy Appoints Interim Surgeon General: Implications for Pharma
Kennedy's appointment of an interim surgeon general could reshape health policy. This article explores the implications for pharmaceutical teams and investors.
Vanda Pharmaceuticals' Imsidolimab Shows Efficacy for Generalized Pustular Psoriasis in NEJM Evidence Study
Vanda Pharmaceuticals announces publication of pivotal Phase III imsidolimab study for generalized pustular psoriasis in NEJM Evidence, supporting BLA submission.